Ultragenyx Pharmaceutical Inc (RARE)

Trade RARE now with
11/29/2021 8:23:54 AM Ultragenyx Reports Addl Positive Multi-Year Durability Data From Phase 1/2 AAV Gene Therapy Studies
11/2/2021 5:17:48 PM Ultragenyx Q3 Loss/share $1.08 Vs. Loss $1.13 Year Ago
8/23/2021 8:33:21 AM Ultragenyx Announces Approval Of Dojolvi In Brazil For Long-chain Fatty Acid Oxidation Disorders In Adults And Children
8/2/2021 4:26:14 PM Ultragenyx Pharma Q2 Loss/share $1.81 Vs. Profit $0.41 Year Ago
7/27/2021 8:49:07 AM Ultragenyx Gets Orphan Drug Designation From FDA And European Commission For UX053 For Glycogen Storage Disease Type III
6/30/2021 8:37:07 AM Ultragenyx Appoints Corsee Sanders To Board Of Directors
6/10/2021 8:48:52 AM Ultragenyx, GeneTx Receive Approval From UK Regulatory Agency To Begin Clinical Study Of GTX-102
5/14/2021 8:37:18 AM Ultragenyx Reports Positive Multi-Year Durability Data From Ongoing Phase 1/2 Gene Therapy Studies
3/8/2021 8:34:18 AM Ultragenyx Announces FDA Clearance Of IND Application For UX053
2/11/2021 4:16:02 PM Ultragenyx Pharma Q4 Loss/share $0.37 Vs. Loss $1.62 Year Ago
1/8/2021 9:05:33 AM Ultragenyx: Durable Response Reported From Phase 1/2 Studies Of DTX401 For GSDIa And DTX301 For OTC
10/27/2020 10:28:52 PM Ultragenyx Pharma Q3 Loss Narrows
10/27/2020 4:20:41 PM Ultragenyx Q3 Net Loss $68.8 Mln Or $1.13/Shr Vs Loss $113.0 Mln Or $1.96/Shr Last Year
9/2/2020 8:14:42 AM Ultragenyx Appoints Mardi Dier As CFO
9/1/2020 8:37:44 AM Ultragenyx Appoints Ernie Meyer As EVP And Chief Human Resources Officer